Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

Abstract

Docetaxel plus 1 multidose day of oral EMP was active in patients with AIPC and was associated with an acceptable toxicity profile. Overall, the therapeutic index of this regimen compared favorably with regimens that employed a longer administration of EMP.